Brain metastasis is a type of cancer that usually occurs due to the spread of cancerous cells to brain. Thus, it is also known as metastatic brain tumor or secondary brain cancer, while in primary brain cancer the tumor occurs in the brain. Brain metastasis is common as compared to the primary brain cancer.Brain metastasis is a major complication of systemic cancer and is one of the major reasons causing morbidity and mortality in cancer patients.The common type of cancer that spread to the brain are breast cancer, lung cancer, melanoma, renal cell carcinoma and colon. The cancer may spread to any part of brain but it is commonly found in the brain cerebrum. Cerebellum and stem cells are rarely found to be affected by brain metastasis. Brain metastasis may be single tumor or multiple, although multiple brain metastasis is common. The symptoms associated with brain metastasis are edema, seizure and severe headache. Therefore the first line of treatment for brain metastasis is treating the symptoms.
Brain Metastasis Therapeutics Market: Drivers & Restraints
The global brain metastasis therapeutics market is driven by the increasing need of treatment for symptoms associated with brain metastasis. Also, the chemotherapeutic agents are known to be the primary tools for cancer treatment which are estimated to increase the overall brain metastasis therapeutic market. The increased prevalence of cancer that spread to the brain are also expected to drive the global metastasis therapeutics market. Though the market seems to be opportunistic in the forecast period there are some factors such as high cost of treatment and side effects associated with the chemotherapy are expected to restrain the growth of brain metastasis therapeutics market.
Request Free Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-1360
Brain Metastasis Therapeutics Market: Segmentation
Brain metastasis therapeutics market is segmented on the basis of treatment type, end user, and region.
Based on treatment, the global brain metastasis therapeutics market is segmented into:
- Radiation therapy
- Targeted therapy
Based on end use, the global brain metastasis therapeutics market is segmented into the following:
- Cancer Hospitals
- Cancer Research Centers
Brain Metastasis Therapeutics Market: Overview
Chemotherapeutic drugs segment would hold maximum market share in overall brain metastasis market owing to widespread availability of variety of chemotherapeutic agents for the brain metastasis cancer treatment. The first line of treatment for brain metastasis is the treatments of symptoms through anticonvulsants and corticosteroids thus the market for these segments are expected to grow at faster rate over the forecast period. According to the American Association of Neurological Surgeons (AANS), in U.S, every year approximately 170,000 new cases of brain metastasis are diagnosed due to which the global brain metastasis market is estimated grow during the forecast period.
Request For TOC@ http://www.futuremarketinsights.com/toc/rep-gb-1360
Brain Metastasis Therapeutics Market: Region-wise Outlook
Depending on geographic regions, global brain metastasis therapeutics market is segmented into seven key regions: North America, South America, Eastern Europe, Western Europe, Asia Pacific, Japan, and Middle East & Africa. Geographically, North America represents the largest regional market for brain metastasis therapeutics owing to high incidence rate of cancer. North America is followed by Europe and APEJ in terms of the increasing incidence of cancer. In Asia Pacific and Latin America, the market is expected to grow due to increase in healthcare awareness, continuously improving economy leading to increased affordability and relatively less competition as compared to that of developed regions of North America and Europe. It is also expected that a large percentage of cases which go unnoticed in developing countries will be recognized with advancing diagnostics and lead to a better market opportunity for therapeutics in Asia pacific.
Brain Metastasis Therapeutics Market: Key Players
Some of the major companies operating in the development and marketing of brain metastasis drugs includes Bayer AG, Pfizer Inc., Sanofi, F. Hoffmann-La Roche Ltd., Eli Lilly & Company, Novartis AG, GlaxoSmithKline, Merck & Co., Inc., AstraZeneca and AngioChem Inc.